Bulletin
Investor Alert

London Markets Open in:

Jan. 24, 2020, 2:48 p.m. EST

Investor Ideas Potcasts, Cannabis News and Stocks on the Move

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Jan 24, 2020 (Investorideas.com via COMTEX) -- Delta, Kelowna, BC - January 24, 2020 (Investorideas.com Newswire) www.Investorideas.com , a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/012420-StocksToWatch.mp3

SHARE PODCAST:

Hear Investor ideas cannabis potcast on iTunes

Today's podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today's podcast we look at a few of this week's announcements.

VIVO Cannabis Inc. ( TSXV: VIVO ) ( OTCQX: VVCIF ) announced that its common shares will begin trading on the Toronto Stock Exchange effective as of market open on January 24, 2020, under the current trading symbol of VIVO . In conjunction with the TSX listing, the Common Shares will be voluntarily delisted from the TSX Venture Exchange.

"The strength of the Toronto Stock Exchange is world-class, and this event represents a tremendous milestone for VIVO," said Barry Fishman, Chief Executive Officer. "We believe the TSX listing will increase VIVO's exposure to a wider audience, increase trading liquidity and expand access to a large new pool of institutional investors."

VIVO has also successfully shipped cannabis 2.0 products from its Canna Farms facility to the provinces of Manitoba and Saskatchewan, with purchase orders to Alberta, Ontario and British Columbia expected to ship imminently.

VIVO also expects to make initial shipments of its Fireside chocolate products, which were created with the founders of award-winning Belgian chocolatier, ChocolaTas, to the provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario, and its Fireside concentrates and vape products from its Vanluven facility to the provinces of Alberta, Ontario, British Columbia and New Brunswick, before the end of Q1 2020.

"We expect that by the end of Q1 2020, our cannabis 2.0 products will be available for sale in seven provinces, which is a significant achievement considering the recent opening of the market," Mr. Fishman continued. "We are proud of our suite of 2.0 products and look forward to our customers having the opportunity to experience them for themselves."

PharmaCielo Ltd. ( TSXV: PCLO ) ( OTCQX: PCLOF ), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced that it has signed a three-year pan-European distribution agreement, in which the Company's high-grade CBD isolate and broad-spectrum CBD oil will be sold to wholesalers and medicinal CPG product manufacturers through GMP certified lab owner, CBD Export Global.

The Agreement with the Quebec, Canada-based CBD Export Global expands PharmaCielo's distribution network in Europe with shipments into the EU to commence in 2020 with increased volumes during the duration of the agreement as B2B markets are expanded. A minimum target volume of 2,000 kg has been agreed to in the first year of the three-year performance-based Agreement, allowing for confirmation of individual market regulatory approvals and enabling increased sales volume expansion in subsequent years.

"The agreement with CBD Export Global is part of PharmaCielo's second-phase growth strategy complementing the first phase in which we established one of the largest cultivation and extraction operations in Colombia and initiated global sales, and now in the second phase expanding the distribution network as production volumes increase on a daily basis to take our high-quality medicinal CBD extracts to global markets," says David Attard, Chief Executive Officer of PharmaCielo. "In 2019 we saw global demand for quality medicinal extracts increasing on an ongoing basis. In 2020 we are further expanding our distribution and sales channels. The collaboration with CBD Export Global will play a key role in our continued growth."

The distribution agreement with CBD Export Global is entered into with the intent of continued market expansion beyond 2019's experience successfully completing commercial shipments of CBD isolate from PharmaCielo to the U.S. and Switzerland.

Aphria Inc. ( TSX: APHA ) ( NYSE: APHA ) announced that it has entered into an agreement to accept a strategic investment from an institutional investor, pursuant to which the Significant Investor has agreed to purchase 14,044,944 units of the Company at a price of C$7.12 per unit for aggregate gross proceeds to the Company of C$100,000,001.

Each unit is comprised of one common share of Aphria and one-half of one common share purchase warrant of Aphria. Each warrant will entitle the Significant Investor to acquire one common share at a price of $9.26 for a period of 24 months from the closing date of the Offering.

The Company intends to use the net proceeds from the Offering to finance international expansion, working capital and general corporate purposes.

The Offering is expected to close on or about January 31, 2020 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Toronto Stock Exchange and the New York Stock Exchange.

"Given the strength of our leadership team, the continued execution of our strategic plan and the robust opportunities we have for growth in the global cannabis industry, we were able to secure this additional capital from a single investor, a significant endorsement of Aphria in these market conditions," commented Carl Merton, Chief Financial Officer. "We expect this strategic investment to strengthen our balance sheet and propel Aphria forward as we continue to differentiate ourselves in the industry."

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.